Skip to main content
. 2020 Sep 10;12(9):2586. doi: 10.3390/cancers12092586

Figure 4.

Figure 4

Combined treatment with the mTOR inhibitor everolimus and both sunitinib and dasatinib results in synergistic cell growth inhibition. (A,C) MDAH2774 and SKOV3 cells were treated with sunitinib, dasatinib, and everolimus, either alone or in combination at the indicated concentrations. Cell viability was determined 72 h later. (B,D) CI was calculated using the Chou–Talalay method. Results are representative of at least three preparations.